Business Of Biotech Commercializing CAR T Cell Therapy With Legend Biotech's Alan Bash
Mar 23, 2026
Alan Bash, biotech executive who led programs at BMS and ran Checkmate and Zeal Bio, now heads Carvykti commercialization at Legend Biotech. He discusses scaling autologous CAR T manufacturing and the Legend–J&J partnership. He covers strategies to expand patient access, educational outreach, preparing for BCMA competitors, and upcoming pipeline moves into allogeneic and in vivo approaches.
AI Snips
Chapters
Transcript
Episode notes
Treat Cash Runway As Oxygen In Small Biotech
- Small biotechs must treat cash runway as oxygen and prioritize strategic choices like partnering, fundraising, or M&A.
- Alan's Checkmate CEO experience showed rapid partnership or acquisition can be the right path when capital is limited.
How The Legend and J&J Partnership Was Born
- Legend and J&J partnered after J&J validated Legend's surprising 2017 ASCO data by reviewing Chinese patient records in person.
- J&J brought global scale and manufacturing (Ghent facilities), while Legend contributed construct knowledge and clinical expertise, enabling rapid commercial expansion.
Data Driven Demand Fueled Carvykti's Early Success
- Carvykti's launch momentum came from standout efficacy and survival data in CARTITUDE-1 that exceeded competitors.
- That data created demand the company couldn't initially meet, producing waiting lists and allocation of treatment slots.